• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Obstacles to the Adoption of Biosimilars for Chronic Diseases.

作者信息

Hakim Aaron, Ross Joseph S

机构信息

Yale University School of Medicine, New Haven, Connecticut.

Section of General Internal Medicine and Robert Wood Johnson Foundation Clinical Scholars Program, Yale University School of Medicine, New Haven, Connecticut3Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut.

出版信息

JAMA. 2017 Jun 6;317(21):2163-2164. doi: 10.1001/jama.2017.5202.

DOI:10.1001/jama.2017.5202
PMID:28459924
Abstract
摘要

相似文献

1
Obstacles to the Adoption of Biosimilars for Chronic Diseases.慢性病生物类似药采用过程中的障碍。
JAMA. 2017 Jun 6;317(21):2163-2164. doi: 10.1001/jama.2017.5202.
2
Pharmaceuticals and Medical Devices: Cost Savings.药品和医疗器械：成本节约。
Issue Brief Health Policy Track Serv. 2016 Dec 27;2016:1-31.
3
Biosimilars for Rheumatoid Arthritis: Don't Count Them Out Quite Yet.类风湿关节炎生物类似药：目前仍不可小觑。
Manag Care. 2018 Jan;27(1):29.
4
[The importance of biosimilars medicines for private and statutory health insurance].[生物类似药对私人医疗保险和法定医疗保险的重要性]
Versicherungsmedizin. 2016 Dec 15;68(4):173-5.
5
Rumors of the Death of Biosimilars Have Been Greatly Exaggerated.生物类似药已死的传言被大大夸大了。
Cancer Invest. 2019;37(8):325-326. doi: 10.1080/07357907.2019.1666515. Epub 2019 Sep 19.
6
Bullying biosimilars: cheaper drugs stymied in USA.打压生物类似药：美国廉价药物受阻
Lancet Gastroenterol Hepatol. 2018 Jun;3(6):371. doi: 10.1016/S2468-1253(18)30126-2.
7
Forum discusses biosimilars, better biologicals.论坛讨论生物类似药及更优质的生物制品。
Am J Health Syst Pharm. 2011 Dec 1;68(23):2210. doi: 10.2146/news110081.
8
Drug Development. Are trade secrets delaying biosimilars?药物研发。商业机密是否在延缓生物类似药的发展？
Science. 2015 Apr 10;348(6231):188-9. doi: 10.1126/science.aab1684. Epub 2015 Apr 9.
9
Biosimilars in the United States: Emerging Issues in Litigation.美国的生物类似药：诉讼中的新问题。
BioDrugs. 2017 Jun;31(3):189-205. doi: 10.1007/s40259-017-0216-7.
10
Friction in the Path to Use of Biosimilar Drugs.生物类似药使用之路上的阻碍
N Engl J Med. 2018 Mar 1;378(9):791-793. doi: 10.1056/NEJMp1714908.

引用本文的文献

1
Beyond Cost: Observations on Clinical and Patient Benefits of Biosimilars in Real-World Settings.超越成本：真实世界中生物类似药的临床及患者获益观察
BioDrugs. 2025 Jul;39(4):537-553. doi: 10.1007/s40259-025-00727-z. Epub 2025 Jun 5.
2
Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health Plans.与美国商业健康计划中生物类似药排除和阶梯治疗限制相关的因素。
BioDrugs. 2023 Jul;37(4):531-540. doi: 10.1007/s40259-023-00593-7. Epub 2023 Apr 1.
3
Switching from Infliximab to Biosimilar in Inflammatory Bowel Disease: A Review of Existing Literature and Best Practices.
炎症性肠病中从英夫利昔单抗转换为生物类似药：现有文献及最佳实践综述
Crohns Colitis 360. 2021 Feb 15;3(1):otaa093. doi: 10.1093/crocol/otaa093. eCollection 2021 Jan.
4
Trends in Use of Granulocyte Colony-Stimulating Factor Following Introduction of Biosimilars Among Adults With Cancer and Commercial or Medicare Insurance From 2014 to 2019.2014 年至 2019 年期间，具有商业或医疗保险的癌症成人患者在生物类似药上市后使用粒细胞集落刺激因子的趋势。
JAMA Netw Open. 2021 Nov 1;4(11):e2133474. doi: 10.1001/jamanetworkopen.2021.33474.
5
Uptake of Biosimilars and Its Economic Implication for the Treatment of Patients with Rheumatoid Arthritis in Korea.韩国接受生物类似药及其对类风湿关节炎患者治疗的经济影响。
J Korean Med Sci. 2021 May 24;36(20):e143. doi: 10.3346/jkms.2021.36.e143.
6
Uptake and cost of biosimilar filgrastim among Medicare and Medicaid populations in 2015-2018.2015-2018 年医疗保险和医疗补助人群中生物类似物非格司亭的使用和费用。
J Manag Care Spec Pharm. 2021 May;27(5):660-666. doi: 10.18553/jmcp.2021.27.5.660.
7
Physician, Practice, and Patient Characteristics Associated With Biosimilar Use in Medicare Recipients.与医疗保险受益人中生物类似药使用相关的医生、实践和患者特征。
JAMA Netw Open. 2021 Jan 4;4(1):e2034776. doi: 10.1001/jamanetworkopen.2020.34776.
8
Reply to Comment on "Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US".对《具有多项孤儿药批准的药物的市场独占权（1983 - 2017年）及其在美国的相关预算影响》评论的回复
Pharmacoeconomics. 2020 Dec;38(12):1375-1376. doi: 10.1007/s40273-020-00973-9. Epub 2020 Nov 9.
9
Assessment of Variation in State Regulation of Generic Drug and Interchangeable Biologic Substitutions.评估州政府对仿制药和可互换生物替代品的监管差异。
JAMA Intern Med. 2021 Jan 1;181(1):16-22. doi: 10.1001/jamainternmed.2020.3588.
10
Shift From Adalimumab Originator to Biosimilars in Denmark.丹麦阿达木单抗由原研药转为生物类似药。
JAMA Intern Med. 2020 Jun 1;180(6):902-903. doi: 10.1001/jamainternmed.2020.0338.